Copyright © 2003 American Medical Association. All rights reserved. From: An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis Arch Dermatol. 2003;139(6):719-727. doi:10.1001/archderm.139.6.719 Figure Legend: Study flow diagram. The asterisk indicates that data shown are the numbers of patients who discontinued treatment during weeks 1 through 12; however, only 7 patients in the placebo group, 2 patients in the 10-mg alefacept group, and 9 patients in the 15-mg alefacept group were withdrawn from the study during weeks 1 through 12. IM indicates intramuscular. Date of download: 9/30/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis Arch Dermatol. 2003;139(6):719-727. doi:10.1001/archderm.139.6.719 Figure Legend: Mean percentage change from baseline in the Psoriasis Area Severity Index. The solid bar indicates the dosing interval; arrow, 2 weeks after the last treatment dose. Date of download: 9/30/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis Arch Dermatol. 2003;139(6):719-727. doi:10.1001/archderm.139.6.719 Figure Legend: Percentage of patients achieving at least 50% Psoriasis Area Severity Index reduction from baseline at each study visit over the treatment and follow-up periods. The solid bar indicates the dosing interval; arrow, 2 weeks after the last treatment dose. Date of download: 9/30/2017 Copyright © 2003 American Medical Association. All rights reserved.

Copyright © 2003 American Medical Association. All rights reserved. From: An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis Arch Dermatol. 2003;139(6):719-727. doi:10.1001/archderm.139.6.719 Figure Legend: Illustration of clinical benefit in a patient treated with 15 mg of alefacept. This patient had a baseline Psoriasis Area Severity Index of 12.4 (A), which was reduced by 54% at 2 weeks after the last dose (B), and by 77% at 12 weeks after the last dose (C). Date of download: 9/30/2017 Copyright © 2003 American Medical Association. All rights reserved.